Sector Update: Healthcare

By
A A A
Share |

Healthcare stocks are ending lower with the NYSE Healthcare Sector Index falling about 0.7% and shares of healthcare companies in the S&P 500 also slipping 0.7% as a group.

In company news, Alnylam Pharmaceutics Inc ( ALNY ) is set to finish nearly 7% lower at $51.21 a share after reporting a Q3 net loss of $0.48 per share, $0.08 wider than the Capital IQ consensus.

Revenues slid 46.4% compared to year-ago levels to $9 million, edging out estimates by around $350,000.

For Q4, ALNY said it expects net revenues from research collaborators to remain consistent with Q3, which included $5.5 million from the company's alliance with Takeda Pharmaceuticals Co. and another $1.4 million in revenue from its collaboration with Monsanto.

In other sector news,

(+) GERN, Mayo Clinic study of its Imetelstat drug candidate found an overall response of 44% in the 18 patients with myelofibrosis evaluable for response, including four patients with complete remissions and another with a partial remission.

(-) BIOS, Break-even Q3, ex items, trails Street view by $0.03. Lowers top end of FY13 revenue forecast by $15 mln to a new range of $830 mln to $850 mln - still in-line with estimates expecting $839.34 mln in revenue.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: ALNY

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM